1. Academic Validation
  2. Androgen-Responsive Oncogenic lncRNA RP11-1023L17.1 Enhances c-Myc Protein Stability in Prostate Cancer

Androgen-Responsive Oncogenic lncRNA RP11-1023L17.1 Enhances c-Myc Protein Stability in Prostate Cancer

  • Int J Mol Sci. 2022 Oct 13;23(20):12219. doi: 10.3390/ijms232012219.
Wenhua Huang 1 Qin Chen 1 Yali Lu 1 Zhe Kong 1 Xuechao Wan 1 Yan Huang 1 Minyan Qiu 1 Yao Li 1
Affiliations

Affiliation

  • 1 State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Science, Fudan University, Shanghai 200433, China.
Abstract

Long noncoding RNAs (lncRNAs) have been found as novel participants in the pathophysiology of prostate Cancer (PCa), which is predominantly regulated by androgen and its receptor. The biological function of androgen-responsive lncRNAs remains poorly understood. Here, we identified that lncRNA RP11-1023L17.1, which is highly expressed in PCa. RP11-1023L17.1 expression, can be directly repressed by the Androgen Receptor in PCa cells. RP11-1023L17.1 depletion inhibited the proliferation, migration, and cell cycle progression, and promoted the Apoptosis of PCa cells, indicating that RP11-1023L17.1 acts as an oncogene in PCa cells. Microarray results revealed that RP11-1023L17.1 depletion downregulated the c-Myc transcription signature in PCa cells. RP11-1023L17.1 depletion-induced cellular phenotypes can be overcome by ectopically overexpressed c-Myc. Mechanistically, RP11-1023L17.1 represses FBXO32 mRNA expression, thereby enhancing c-Myc protein stability by blocking FBXO32-mediated c-Myc degradation. Our findings reveal the previously unrecognized roles of RP11-1023L17.1 in c-Myc-dependent PCa tumorigenesis.

Keywords

RP11-1023L17.1; androgen-responsive lncRNA; c-Myc; prostate cancer (PCa).

Figures
Products